1 Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination

2 in solid organ transplant recipients

- 3 Alexandra Tauzin^{1,2}, Guillaume Beaudoin-Bussières^{1,2}, Shang Yu Gong^{1,3}, Debashree Chatterjee¹,
- 4 Gabrielle Gendron-Lepage¹, Catherine Bourassa¹, Guillaume Goyette¹, Normand Racine⁴, Zineb Khrifi¹,
- 5 Julie Turgeon^{1,5}, Cécile Tremblay^{1,2}, Valérie Martel-Laferrière^{1,2}, Daniel E. Kaufmann^{1,6}, Marc Cloutier⁷, 6 Renée Bazin⁷, Ralf Duerr⁸, Mélanie Dieudé^{1,2,5}, Marie-Josée Hébert^{1,5,6*}, Andrés Finzi^{1,2,3,9,*}
- 7 ¹Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada
- 8 ²Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, H2X 9 0A9, Canada
- 10 ³Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada
- 11 ⁴Institut Cardiologie de Montréal, Montreal, QC, H1T 1C8, Canada
- 12 ⁵Canadian Donation and Transplantation Research Program (CDTRP), Edmonton, AL, T6G 2E1, Canada
- 13 ⁶Département de Médecine, Université de Montréal, Montreal, QC, H3T 1J4, Canada
- 14 ⁷Héma-Québec, Affaires Médicales et Innovation, Québec, QC, G1V 5C3, Canada
- 15 ⁸Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA 16
- 17

- 18 ⁹Lead contact
- 19 *Correspondence: andres.finzi@umontreal.ca (A.F.) 20
 - marie-josee.hebert@umontreal.ca (M.J.H.)
- 22 Summary word count:
- 23 24 Character count:

25 SUMMARY

26 While SARS-CoV-2 mRNA vaccination has been shown to be safe and effective in the 27 general population, immunocompromised solid organ transplant recipients (SOTR) were reported 28 to have impaired immune responses after one or two doses of vaccine. In this study, we examined 29 humoral responses induced after the second and the third dose of mRNA vaccine in different 30 SOTR (kidney, liver, lung and heart). Compared to a cohort of SARS-CoV-2 naïve 31 immunocompetent health care workers (HCW), the second dose induced weak humoral 32 responses in SOTR, except for the liver recipients. The third dose boosted these responses but 33 they did not reach the same level as in HCW. Interestingly, while the neutralizing activity against Delta and Omicron variants remained very low after the third dose, Fc-mediated effector functions 34 35 in SOTR reached similar levels as in the HCW cohort. Whether these responses will suffice to 36 protect SOTR from severe outcome remains to be determined.

37

38

KEYWORDS: Solid organ transplant recipients, Vaccination, Coronavirus, COVID-19, SARSCoV-2, Spike glycoproteins, Humoral responses, Neutralization, ADCC, Variants of concern

41 INTRODUCTION

42 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent 43 of the coronavirus disease 2019 (COVID-19) responsible of the current pandemic. COVID-19 44 causes a plethora of symptoms with different degrees of severity (Sheikhi et al., 2020). In solid 45 organ transplant recipients (SOTR), due to immunosuppressive treatments, SARS-CoV-2 infection leads to a high rate of severe COVID-19 (Danziger-Isakov et al., 2021; Pereira et al., 46 47 2020) and therefore vaccination is strongly recommended (AST, 2022; CST, 2022). The Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 mRNA vaccines have shown a 48 49 remarkable efficacy in the general population, particularly against severe outcomes (Baden et al., 50 2021; Polack et al., 2020). However, in SOTR, immune responses induced by vaccination are 51 generally reduced (Kumar et al., 2011; Stucchi et al., 2018) and recent studies have shown that 52 SOTR have impaired humoral responses after two doses of the SARS-CoV-2 mRNA vaccine 53 (Caillard et al., 2021; Miele et al., 2021; Rabinowich et al., 2021; Rincon-Arevalo et al., 2021; 54 Stumpf et al., 2021).

Moreover, SARS-CoV-2 is constantly evolving, and the Wuhan original strain has now 55 56 been replaced by several variants. Among current circulating strains, the Delta and Omicron 57 variants of concern (VOCs) have accumulated numerous mutations in their genome, and notably 58 in the Spike (S) glycoprotein (Kumar et al., 2022). Because of the mutations, these VOCs are 59 transmitted more efficiently than the original Wuhan strain and less well controlled by vaccination 60 (Kumar et al., 2022; Lauring et al., 2022; Tseng et al., 2022). However, the administration of a 61 third dose of mRNA vaccine (boost) leads to strong humoral responses and protects from severe 62 outcome caused by these VOCs in the general population (Ariën et al., 2022; Tauzin et al., 2022a; 63 Yoon et al., 2022). However, humoral responses elicited by the third dose on populations with 64 compromised immune responses, particularly SOTR, are less documented. Here, we evaluated

- 65 humoral responses induced in different groups of SOTR (kidney, liver, lung and heart) after the
- 66 second and third doses of the mRNA vaccine.

67 **RESULTS**

68 We analyzed humoral immune responses in cohorts of 31 kidney, 11 liver, 14 lung and 8 69 heart organ transplant recipients after the second (median [range]: 26 days [20-54 days]) and 70 third doses (median [range]: 35 days [19–68 days]) of SARS-CoV-2 mRNA vaccine. The SOTR 71 received their first two doses with different interval regimen (median [range]: 36 days [25-112 days]) and their third dose around 4 months after the second dose (median [range]: 110 days 72 73 [34–195 days]), according to the province of Quebec, Canada public health authority's vaccination 74 roll out guidelines for immunocompromised patients. Vaccine-elicited humoral responses in 75 SOTR were compared to those measured in a cohort of SARS-CoV-2 naïve health care workers 76 (HCW). HCW received their first two doses of mRNA vaccine with a 16-week extended interval 77 (median [range]: 111 days [76–134 days]), and their third dose around seven months after the 78 second dose (median [range]: 219 days [167-235 days]), according to the province of Quebec, 79 Canada public health authority's vaccination roll out guidelines for HCW. Several studies have 80 shown that this extended interval regimen leads to strong humoral and cellular responses after 81 the second dose, notably against VOCs (Chatterjee et al., 2022; Nayrac et al., 2021; Payne et al., 82 2021; Tauzin et al., 2022a). This allowed us to compare humoral responses obtained in SOTR versus humoral responses elicited by a long interval vaccination regimen. Basic demographic 83 84 characteristics of the cohorts, immunosuppressive treatments of the SOTR and detailed 85 vaccination time points are summarized in Table 1 and Figure 1A.

86

87 Elicitation of SARS-CoV-2 antibodies against the receptor-binding domain of the Spike

We first measured anti-receptor-binding domain (RBD) IgG levels induced after the second and the third doses of the mRNA vaccine using a previously reported ELISA assay (Anand et al., 2021; Beaudoin-Bussières et al., 2020; Prévost et al., 2020; Tauzin et al., 2021). After the second dose, all HCW presented high levels of RBD-specific IgG (Figure 1B). In contrast, in all

92 groups of SOTR, the levels of anti-RBD antibodies (Abs) were, with the exception of liver 93 recipients, significantly lower than in HCW. We also noted that in every SOTR group, some donors 94 did not have anti-RBD IgG after the second dose of mRNA vaccine. Among SOTR, liver recipients 95 had higher Ab levels than kidney, lung and heart recipients, in line with a generally lower 96 immunosuppression regimen. For HCW, the third dose of the mRNA vaccine led to the same level 97 of Abs as after the second dose, as recently described (Tauzin et al., 2022a). For SOTR, we 98 observed a significant increase in the level of anti-RBD IgG in lung recipients and a trend for 99 kidnev and heart recipients. No increase in anti-RBD IgG level was observed for liver recipients. 100 Of note, in all SOTR groups, anti-RBD levels remained significantly lower than in the HCW cohort 101 even after the third dose, but most donors who did not have anti-RBD IgG after the second dose 102 developed antibodies after the third dose, suggesting the initiation of an antibody response by 103 repeated antigen exposure.

104

105 **Recognition of SARS-CoV-2 Spike variants and a common-cold human Betacoronavirus**

106 We next evaluated the recognition of the SARS-CoV-2 full-length S after vaccination in 107 SOTR and HCW by flow cytometry (Figure 2A). After the second vaccine dose, no significant 108 differences were observed in the recognition of the D614G S by plasma from kidney and liver 109 recipients and HCW. In contrast, lung and heart recipients recognized the D614G S less 110 efficiently. The third dose increased the D614G S recognition for HCW, and we noted a slight 111 increase for lung and heart recipients, for whom the recognition was very weak after the second 112 dose. For kidney and liver recipients, the third dose did not improve the D614G S recognition 113 (Figure 2A).

114 It has been well documented that Delta and Omicron VOCs are less efficiently recognized 115 by Abs induced by vaccination, because of accumulated mutations in the S glycoproteins 116 compared to the original Wuhan strain, used for the development of current mRNA SARS-CoV-2 117 vaccines (Chatterjee et al., 2022; Planas et al., 2021; Tauzin et al., 2022a). We measured the

118 recognition of these VOCs S after mRNA vaccination in SOTR (Figure 2B-C). We did not see 119 significant differences in the level of recognition of Delta and Omicron S between liver recipients 120 and HCW after the second dose. The third dose led to a slight increase of the recognition of the 121 VOCs S except for liver recipients, however it remained significantly lower than in HCW. When we compared S recognition between the SARS-CoV-2 variants (Figure S1), we observed that in 122 123 HCW, because of strong humoral responses induced by the extended interval, no major 124 differences in recognition were observed between D614G and VOCs S after the second and third 125 doses of mRNA vaccine (Figure S1A). For SOTR, VOCs S were significantly less recognized than 126 the D614G S, suggesting that vaccination in SOTR did not improve the breadth of S recognition, 127 as observed in HCW (Figure S1B-E).

We also evaluated the recognition of the human HKU1 *Betacoronavirus* S glycoprotein (Figure 2D). HKU1 is an endemic coronavirus that causes common colds and is highly prevalent in the population (Chan et al., 2009; Rees et al., 2021). No significant differences between HCW and SOTR were observed after the second and the third doses of the vaccine, indicating that transplantation and associated immunosuppression regimens did not affect the level of circulating Abs elicited before vaccination.

134

135 Functional activities of vaccine-elicited antibodies

136 We evaluated functional activities of vaccine-elicited Abs after the second and third doses 137 of mRNA vaccine (Figure 3). We measured Fc-mediated effector functions using a well-described 138 antibody-dependent cellular cytotoxicity (ADCC) assay (Anand et al., 2021; Beaudoin-Bussières 139 et al., 2020, 2021; Ullah et al., 2021). Plasma from HCW presented robust ADCC activity after 140 the second dose that was restored to the same level by the third dose (Figure 3A). The second 141 dose elicited ADCC-mediating Abs in liver and heart recipients that reached similar levels of 142 activity as in HCW. This is in contrast with significant lower ADCC activity elicited after the second 143 dose in kidney and lung recipients. The boost led to a significant increase in ADCC activity in

these donors. Importantly, the third dose elicited ADCC activity in all SOTR similar to the oneobserved in HCW.

We also measured the neutralizing activity of the vaccine-induced Abs, against pseudoviruses carrying SARS-CoV-2 S (Figure 3B-D). When assessing the neutralizing activity against the D614G S, we observed that the second dose elicited Abs with neutralizing activity in liver recipients (Figure 3B). In other SOTR, very low levels of neutralizing Abs were detected, especially in lung recipients. As observed for ADCC activity, the boost increased the neutralization activity in kidney and lung recipients. However, even after the third dose, SOTR did not reach the same levels of neutralizing Abs as in HCW.

We also measured the neutralizing activity against pseudoviruses carrying the Delta and Omicron Spikes (Figure 3C-D). In HCW, the second dose of mRNA vaccine administered with a 16-weeks interval, led to high levels of Abs able to neutralize these variants, as previously described (Chatterjee et al., 2022; Payne et al., 2021; Tauzin et al., 2022a). In contrast, SOTR elicited very low levels of neutralizing Abs against Delta and Omicron variants after the second dose and, although the boost led to a slight increase of the neutralization activity, this remained significantly lower than in HCW.

When comparing the neutralizing activity between the SARS-CoV-2 variants (Figure S2), Delta was less efficiently neutralized in HCW than D614G at the two different time points (Figure S2A). For kidney and liver recipients, Omicron and Delta VOCs were less neutralized than D614G (Figure S2B-C). For other SOTR, neutralization activity was too weak to measure significant differences (Figure S2D-E).

165

166 Anti-RBD avidity of vaccine-elicited antibodies

167 We also used a surrogate assay for antibody maturation by measuring the avidity for the 168 RBD of vaccine-elicited Abs, using a previously described assay (Björkman et al., 1999; Fialová 169 et al., 2017; Tauzin et al., 2022a, 2022b, 2022c). Briefly, plasma samples were tested in parallel

by ELISA with washing steps having or not having a chaotropic agent (8M urea), measuring respectively the level of IgG with high avidity for the RBD and the level of total anti-RBD IgG. The RBD-avidity index corresponds to the proportion of high avidity IgG among the total anti-RBD IgG (Figures 4), and provides an overall idea of antibody maturation (Björkman et al., 1999; Fialová et al., 2017; Tauzin et al., 2022a, 2022b, 2022c).

175

In HCW, the second dose of the mRNA vaccine elicited IgG with high avidity, that was not further improved by the boost (Figure 4), as recently described (Tauzin et al., 2022a). In contrast, in SOTR who developed Abs able to recognize the RBD, the avidity was significantly lower than in HCW (Figure 1B and 4). The third dose of mRNA vaccine increased RBD avidity in SOTR but, with the exception of liver recipients, remained significantly lower than in HCW.

181

182 Integrated analysis of vaccine responses elicited in solid organ transplant recipients

183 We evaluated the network of pairwise correlations among all studied immune variables on 184 the HCW and the different SOTR groups (Figure 5). For HCW, we observed that after the second 185 dose all immune variables tested were involved in a dense network of positive correlations. After 186 the boost, we did not observe major differences in the network of correlations, suggesting that the 187 third dose did not induce qualitatively different humoral responses in HCW. For lung and heart 188 recipients, who received the strongest immunosuppressive regimens, we observed that all 189 immune variables were very weakly interconnected after the second dose and the third dose did 190 not strongly increase the network. Immune variables were slightly more interconnected for kidney 191 recipients, which aligns with their lower immunosuppressive regimen compared to heart and lung 192 recipients. For liver recipients, the network of correlation was less dense than in HCW after the 193 second dose as observed for the other groups of SOTR. Interestingly, in this less 194 immunosuppressed group of SOTR, the third dose of the mRNA vaccine induced a dense network 195 of correlations, which was in a comparable range as in HCW.

196 **DISCUSSION**

While a large part of the world population is vaccinated with two or three doses of SARS-CoV-2 vaccines, some population groups remain vulnerable to SARS-CoV-2 infection and most importantly to severe outcomes. Here we show that SOTR, known to respond less efficiently to vaccination due to their chronic immunosuppressive regimen (Kumar et al., 2011; Stucchi et al., 2018), elicited poor humoral responses after the second dose of SARS-CoV-2 mRNA vaccine, compared to HCW. The boost induced an increase of these responses, but they did not reach the same level as observed in HCW.

204

205 An important concern about the evolving pandemic is the frequent apparition of variants. 206 It was previously shown that the 3-4 weeks standard interval of vaccination leads to weak 207 neutralizing Abs against several VOCs in the general population (Chatterjee et al., 2022; Payne 208 et al., 2021; Tauzin et al., 2022a, 2022c). However, administering a boost strongly enhances the 209 breadth of neutralization activity against these variants (Nemet et al., 2022; Schmidt et al., 2022; 210 Tauzin et al., 2022a). In SOTR, we did not observe a significant increase in the breadth of 211 recognition and neutralization of these variants, suggesting an inability in Abs maturation in most 212 of these individuals. This is supported by the poor anti-RBD avidity detected in these individuals, 213 likely reflecting poor B cells maturation compared to HCW.

214

215 Interestingly, we observed that SOTR elicited Abs with ADCC activity comparable to HCW 216 after the third dose of the mRNA vaccine. There is increasing evidence showing that Fc-mediated 217 effector functions play an important role in the protection against severe outcomes of SARS-CoV-218 2 (Anand et al., 2021; Richardson et al., 2022; Tauzin et al., 2021). However, whether this will 219 suffice to protect SOTR from severe outcomes caused by SARS-CoV-2 remains unknown.

220

221 We also noted some differences in humoral responses, depending on the transplanted organ. Notably, we observed that liver recipients had better humoral responses than other SOTR 222 223 groups. These differences are probably due to the lower immunosuppressive regimens in liver 224 recipients than in other SOTR groups. Further work is needed to understand the correlation between specific immunosuppressive regimens and vaccination outcome, taking into account the 225 226 dose and type of immunosuppressive agents, and response to SARS-CoV-2 vaccines. This also 227 highlights the importance of evaluating the different SOTR groups independently regarding the 228 decisions on the follow-up of vaccinations that needs to be adapted to each SOTR group.

229

230

231 ACKNOWLEDGMENTS

232 The authors are grateful to the donors who participated in this study. The authors thank 233 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. M. 234 Gordon Joyce (U.S. MHRP) for the monoclonal antibody CR3022. We also thank Demitra Yotis, 235 Amani Mahroug, Yizou Zhao and Annie Karakeussian Rimbaud for their contribution on the 236 transplant cohort. The graphical abstract was created using BioRender.com. This work was 237 supported by le Ministère de l'Économie et de l'Innovation du Québec. Programme de soutien 238 aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM. This work 239 was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and 240 Health Emergencies Research grant #177958, to A.F., and by an Exceptional Fund COVID-19 241 from the Canada Foundation for Innovation (CFI) #41027 to D.E.K. and A.F. This work was also 242 supported by a FRQS Pandemic Initiatives COVID-19 grant #308941 to M.J.H and in-kind 243 contribution from Canadian Donation and Transplantation Research Program (CDTRP). Work on 244 variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ 245 in collaboration with Fonds de Recherche du Québec Santé (FRQS) to A.F. A.F. is the recipient

of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. M.-J. H. holds the
Shire Chair in Nephrology, Transplantation and Renal Regeneration of Université de Montréal.
C.T holds the Pfizer/Université de Montréal Chair on HIV translational research. V.M.L. is
supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS Merit Research Scholar. G.B.B.
is the recipient of a FRQS PhD fellowship. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript. We declare no competing
interests.

253

254 AUTHOR CONTRIBUTIONS

A.T., M.D., M.J.H. and A.F. conceived the study. A.T., G.B.B., S.Y.G., D.C., C.B., P.L., G.G.L. M.D., M.J.H. and A.F. performed, analyzed, and interpreted the experiments. A.T. and R.D. performed statistical analysis. G.B.B., S.Y.G., G.G.L., G.G., J.T., M.D., M.J.H. and A.F. contributed unique reagents. N.R., Z.K. C.T., D.E.K., M.J.H. and V.M.-L. collected and provided clinical samples. D.E.K., M.C., R.B., M.D., M.J.H. and A.F provided scientific input. A.T., and A.F. wrote the manuscript with inputs from others. Every author has read, edited, and approved the final manuscript.

262

263 DECLARATION OF INTERESTS

264 The authors declare no competing interests.

266 FIGURE LEGENDS

Figure 1. Elicitation of RBD-specific antibodies in SOTR and HCW after mRNA vaccination.

268 (A) SARS-CoV-2 vaccine cohorts' design. (B) Indirect ELISA was performed by incubating 269 plasma samples from SOTR or HCW with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab 270 binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values 271 obtained with BSA (negative control) were subtracted and further normalized to the signal 272 obtained with the anti-RBD CR3022 mAb presents in each plate. Left panel shows the values 273 obtained after the second dose, and **middle panel** after the third dose. **Right panel** shows the 274 difference obtained between D2 (post second dose) and D3 (post third dose) for every group. 275 Symbols represent biologically independent samples from SOTR and HCW. Lines connect data 276 from the same donor. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* p < 0.05; ** p < 0.01; *** p < 0.001; **** 277 278 p < 0.0001; ns, non-significant).

279

Figure 2. Binding of vaccine-elicited antibodies to SARS-CoV-2 Spike variants and the human HKU1 *Betacoronavirus* in SOTR and HCW after mRNA vaccination.

282 293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants 283 and HCoV-HKU1 and stained with the CV3-25 Ab or with plasma from SOTR or HCW. The values 284 represent the median fluorescence intensities (MFI) normalized by CV3-25 Ab binding (**A-C**) or 285 the MFI (**D**). **Left panel** shows the values obtained after the second dose, and **middle panel** after 286 the third dose. **Right panel** shows the differences obtained between D2 (post second dose) and 287 D3 (post third dose) for every group. Symbols represent biologically independent samples from 288 SOTR and HCW. Lines connect data from the same donor. Undetectable measures are

represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns, non-significant).

291

Figure 3. Fc-mediated effector functions and neutralization activities in SOTR and HCW after mRNA vaccination.

294 (A) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-Spike cells and were used 295 as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based 296 ADCC assay. (B-D) Neutralizing activity was measured by incubating pseudoviruses bearing 297 SARS-CoV-2 S glycoproteins ((B) D614G, (C) Delta and (D) Omicron), with serial dilutions of 298 plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory 299 serum dilution (ID₅₀) values were determined using a normalized non-linear regression using 300 GraphPad Prism software. Left panel shows the values obtained after the second dose, and 301 middle panel after the third dose. Right panel shows the differences obtained between D2 (post 302 second dose) and D3 (post third dose) for every group. Symbols represent biologically 303 independent samples from SOTR and HCW. Lines connect data from the same donor. 304 Undetectable measures are represented as white symbols, and limits of detection are plotted. 305 Error bars indicate means ± SEM. (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns, non-306 significant).

307

Figure 4. Anti-RBD avidity of vaccine-elicited antibodies in SOTR and HCW after mRNA vaccination.

Indirect ELISA and stringent ELISA were performed by incubating plasma samples from SOTR
 and HCW with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using
 HRP-conjugated anti-human IgG. The RBD avidity index corresponded to the RLU value obtained

for every plasma sample with the stringent (8M urea) ELISA divided by that obtained with the 0M urea ELISA. **Left panel** shows the values obtained after the second dose, and **middle panel** after the third dose. **Right panel** shows the differences obtained between D2 (post second dose) and D3 (post third dose) for every group. Symbols represent biologically independent samples from SOTR and HCW. Lines connect data from the same donor. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (* p < 0.05; ** p < 0.01; **** p < 0.0001; ns, non-significant).

320

Figure 5. Mesh correlations of humoral response variables in SOTR and HCW after mRNA vaccination.

Edge bundling correlation plots where red and blue edges represent positive and negative correlations between connected variables, respectively. Only significant correlations (p < 0.05, Spearman rank test) are displayed. Nodes are color coded based on the grouping of variables according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge bundling plots are shown for correlation analyses using ten different datasets, i.e., HCW and kidney, liver, lung or heart transplant recipients after the second and third doses of mRNA vaccination.

330

332

Table 1. Characteristics of the SARS-CoV-2 vaccinated SOTR and HCW cohorts

			SOTR				
		нсw	Entire cohort	Kidney	Liver	Lung	Heart
Age		52 (33 - 64)	46 (21 - 82)	46 (23 - 73)	44 (21 - 59)	38 (26 - 59)	66 (58 - 82)
Sex	Male (n)	8	39	19	7	7	6
	Female (n)	12	25	12	4	7	2
Immunosuppression	Prednisone (n)	N/A	47	30	4	13	0
	Tacrolimus (n)	N/A	58	28	10	14	6
	Mycophenolate mofetil/mucophenolate sodium (n)	N/A	49	26	2	13	8
	Cyclosporin (n)	N/A	2	1	0	0	1
	Sirolimus (n)	N/A	4	2	1	0	1
	Azathioprine (n)	N/A	4	1	2	1	0
Years between transplantation and the 1 st dose ^a		N/A	3.90 (-0.40 – 36.28)	2.04 (-0.40 – 22.93)	3.50 (0.66 – 36.28)	3.66 (0.36 – 20.07)	11.41 (3.20 – 23.65)
Days between the 1 st and 2 nd dose ^a		111 (76- 120)	36 (25 – 112)	34 (28 – 75)	37 (28 – 112)	32 (25 – 92)	84 (62 – 101)
Days between the 2 nd and 3 rd dose ^a		219 (167- 230)	110 (34 - 195)	111 (34 - 153)	113 (74 -147)	104 (81 - 169)	81 (78 - 195)
Days between the 2 nd dose and D2 ^a		21 (17-34)	26 (20 - 54)	27 (22 - 45)	26 (22 - 35)	26 (22 - 28)	28 (20 - 54)
Days between the 3 rd dose and D3 ^a		27 (20-38)	35 (19 - 68)	35 (19 - 48)	35 (21 - 55)	42 (28 - 68)	30 (22 - 51)

333

^a Values displayed are medians, with ranges in parentheses.

335	STAR METHODS							
336								
337	RESOURCE AVAILABILITY							
338								
339	Lead contact							
340	Further information and requests for resources and reagents should be directed to and will be							
341	fulfilled by the lead contact, Andrés Finzi (andres.finzi@umontreal.ca).							
342								
343	Materials availability							
344	All unique reagents generated during this study are available from the Lead contact withou							
345	restriction.							
346								
347	Data and code availability							
348	 All data reported in this paper will be shared by the lead contact 							
349	(andres.finzi@umontreal.ca) upon request.							
350	This paper does not report original code.							
351	• Any additional information required to reanalyze the data reported in this paper is available							
352	from the lead contact (andres.finzi@umontreal.ca) upon request.							
353								
354								

355 EXPERIMENTAL MODEL AND SUBJECT DETAILS

356

357 Ethics Statement

All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at CHUM (19.381 and 21.001). Plasmas were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C until use.

363 Human subjects

The study was conducted in 20 SARS-CoV-2 naïve vaccinated HCW (8 males and 12 females; age range: 33-64 years) and 64 SARS-CoV-2 vaccinated SOTR (39 males and 25 females; age range: 21-82 years). All this information is summarized in table 1. For SARS-CoV-2 naïve vaccinated HCW cohort, no specific criteria such as number of patients (sample size), gender, clinical or demographic were used for inclusion, beyond no detection of Abs recognizing the N protein. For SARS-CoV-2 vaccinated SOTR, greater than 1-month post-transplant at the time of enrolment was used for inclusion.

371

372 Plasma and antibodies

Plasma from SOTR and HCW were collected, heat-inactivated for 1 hour at 56°C and stored at -80°C until ready to use in subsequent experiments. Plasma from uninfected donors collected before the pandemic were used as negative controls and used to calculate the seropositivity threshold in our ELISA, ADCC and flow cytometry assays (see below). The RBD-specific monoclonal antibody CR3022 was used as a positive control in our ELISA, and the CV3-25 antibody in flow cytometry assays and were previously described (Anand et al., 2020; Beaudoin-Bussières et al., 2020; Jennewein et al., 2021; Meulen et al., 2006; Prévost et al., 2020). Horseradish peroxidase (HRP)-conjugated Abs able to recognize the Fc region of human IgG (Invitrogen) were used as secondary Abs in ELISA experiments. Alexa Fluor-647-conjugated goat anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect plasma binding in flow cytometry experiments.

385

386 Cell lines

387 293T human embryonic kidney cells (obtained from ATCC) were maintained at 37°C under 5% 388 CO₂ in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal bovine serum 389 (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). CEM.NKr CCR5+ cells (NIH AIDS 390 reagent program) and CEM.NKr.Spike cells were maintained at 37°C under 5% CO₂ in Roswell 391 Park Memorial Institute (RPMI) 1640 medium (Gibco) containing 10% FBS and 100 µg/ml of 392 penicillin-streptomycin. 293T-ACE2 cell line was previously reported (Prévost et al., 2020). 393 CEM.NKr CCR5+ cells stably expressing the SARS-CoV-2 S glycoprotein were previously 394 reported (Anand et al., 2021; Beaudoin-Bussières et al., 2021).

395

396 METHOD DETAILS

397 Plasmids

The HCoV-HKU1 S expressing plasmid was purchased from Sino Biological. The plasmids encoding the different SARS-CoV-2 Spike variants (D614G, Delta and Omicron) were previously described (Beaudoin-Bussières et al., 2020; Chatterjee et al., 2022; Gong et al., 2021; Tauzin et al., 2021, 2022c).

402

403 **Protein expression and purification**

404 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density 405 of 1×10^6 cells/mL at 37°C with 8 % CO₂ with regular agitation (150 rpm). Cells were transfected

with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussières et al., 2020) using ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

413

414 Enzyme-Linked Immunosorbent Assay (ELISA) and RBD avidity index

415 The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussières et al., 416 2020; Prévost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 µg/ml) were 417 prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells 418 were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1% 419 Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with 420 washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml) 421 or a 1/250 dilution of plasma were prepared in a diluted solution of blocking buffer (0.1 % BSA) 422 and incubated with the RBD-coated wells for 90 minutes at room temperature. Plates were 423 washed four times with washing buffer followed by incubation with secondary Abs (diluted in a 424 solution of blocking buffer (0.4% BSA)) for 1h at room temperature, followed by four washes. To 425 calculate the RBD-avidity index, we performed in parallel a stringent ELISA, where the plates 426 were washed with a chaotropic agent, 8M of urea, added of the washing buffer. This assay was 427 previously described (Tauzin et al., 2022b). HRP enzyme activity was determined after the 428 addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life 429 Sciences). Light emission was measured with a LB942 TriStar luminometer (Berthold 430 Technologies). Signal obtained with BSA was subtracted for each plasma and was then 431 normalized to the signal obtained with CR3022 present in each plate. The seropositivity threshold

432 was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative
433 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

434

435 Cell surface staining and flow cytometry analysis

436 293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination 437 with plasmid encoding the full-length S of SARS-CoV-2 variants (D614G, Delta or Omicron) or 438 the HCoV-HKU1 S. 48h post-transfection, S-expressing cells were stained with the CV3-25 Ab 439 (Jennewein et al., 2021) or plasma (1/250 dilution). Alexa Fluor-647-conjugated goat anti-human 440 IgM+IgG+IgA Abs (1/800 dilution) were used as secondary Abs. The percentage of transfected 441 cells (GFP+ cells) was determined by gating the living cell population based on viability dye 442 staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences), 443 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The seropositivity threshold 444 was established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative 445 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma). The 446 conformational-independent S2-targeting mAb CV3-25 was used to normalize Spike expression 447 and was shown to effectively recognize all SARS-CoV-2 Spike variants (Li et al., 2022).

448

449 ADCC assay

450 This assay was previously described (Anand et al., 2021; Beaudoin-Bussières et al., 2021). For 451 evaluation of anti-SARS-CoV-2 ADCC, parental CEM.NKr CCR5+ cells were mixed at a 1:1 ratio 452 with CEM.NKr cells stably expressing a GFP-tagged full length SARS-CoV-2 Spike 453 (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained for viability (AquaVivid; Thermo 454 Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell proliferation dye eFluor670; Thermo 455 Fisher Scientific) to be used as target cells. Overnight rested PBMCs were stained with another 456 cellular marker (cell proliferation dye eFluor450: Thermo Fisher Scientific) and used as effector 457 cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates.

458 Plasma (1/500 dilution) were added to the appropriate wells. The plates were subsequently 459 centrifuged for 1 min at 300g, and incubated at 37°C, 5% CO₂ for 5 hours before being fixed in a 460 2% PBS-formaldehyde solution. ADCC activity was calculated using the formula: [(% of GFP+ 461 cells in Targets plus Effectors)-(% of GFP+ cells in Targets plus Effectors plus 462 plasma/antibody)]/(% of GFP+ cells in Targets) x 100 by gating on transduced live target cells. All 463 samples were acquired on an LSRII cytometer (BD Biosciences) and data analysis was performed 464 using FlowJo v10.7.1 (Tree Star). The specificity threshold was established using the following 465 formula: (mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the 466 mean of pre-pandemic SARS-CoV-2 negative plasma).

467

468 Virus neutralization assay

469 To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-470 Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein 471 (D614G, Delta or Omicron) at a ratio of 10:1. Two days post-transfection, cell supernatants were 472 harvested and stored at -80°C until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a density of 1×10⁴ cells/well in 96-well luminometer-compatible tissue culture 473 474 plates (Perkin Elmer) 24h before infection. Pseudoviral particles were incubated with several 475 plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to 476 the target cells followed by incubation for 48h at 37°C. Then, cells were lysed by the addition of 477 30 µL of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar 478 luminometer (Berthold Technologies) was used to measure the luciferase activity of each well 479 after the addition of 100 µL of luciferin buffer (15mM MgSO₄, 15mM KPO₄ [pH 7.8], 1mM ATP, 480 and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin potassium salt (Prolume). The neutralization 481 half-maximal inhibitory dilution (ID₅₀) represents the plasma dilution to inhibit 50% of the infection 482 of 293T-ACE2 cells by pseudoviruses.

483

484 QUANTIFICATION AND STATISTICAL ANALYSIS

485 Statistical analysis

486 Symbols represent biologically independent samples from SOTR and HCW. Lines connect data 487 from the same donor. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad, 488 San Diego, CA). Every dataset was tested for statistical normality and this information was used 489 to apply the appropriate (parametric or nonparametric) statistical test. Differences in responses 490 for the same donor after the second and third dose of mRNA vaccine were performed using Mann-491 Whitney tests. Differences in responses between HCW and SOTR at D2 or D3 were measured 492 by Kruskal-Wallis tests. P values < 0.05 were considered significant; significance values are 493 indicated as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Spearman's R correlation 494 coefficient was applied for correlations. Statistical tests were two-sided and p < 0.05 was 495 considered significant.

496

497 Software scripts and visualization

Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph,
tidyverse, and RColorBrewer packages (R Core Team, 2014). Edges are only shown if p < 0.05,
and nodes are sized according to the connecting edges' r values. Nodes are color-coded
according to groups of variables.

502

503 SUPPLEMENTAL INFORMATION

504 Supplemental information can be found online at ...

505 **REFERENCES**

Anand, S.P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M.-J.,
 Lewin, A., Bazin, R., and Finzi, A. (2020). High-throughput detection of antibodies targeting the
 SARS-CoV-2 Spike in longitudinal convalescent plasma samples (Microbiology).

Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard,
N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of humoral
immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months postsymptom onset. Cell Rep. Med. 100290. https://doi.org/10.1016/j.xcrm.2021.100290.

Ariën, K.K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S., Willems, B.,
Pannus, P., Martens, G.A., Van Esbroeck, M., et al. (2022). Three doses of BNT162b2 vaccine
confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. Npj Vaccines 7,
1–3. https://doi.org/10.1038/s41541-022-00459-z.

AST (2022). Joint Statement about COVID-19 Vaccination in Organ Transplant Candidates and
 Recipients, https://www.myast.org/sites/default/files/03-13-22%20ISHLT-AST ASTS%20joint%20society%20guidance%20vaccine_v9.pdf.

Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector,
S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARSCoV-2 Vaccine. N. Engl. J. Med. *384*, 403–416. https://doi.org/10.1056/NEJMoa2035389.

Beaudoin-Bussières, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,
Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral Responses
against SARS-CoV-2 Spike in Convalescent Individuals. MBio 11.
https://doi.org/10.1128/mBio.02590-20.

527 Beaudoin-Bussières, G., Richard, J., Prévost, J., Goyette, G., and Finzi, A. (2021). A new flow 528 cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-529 expressing cells. STAR Protoc. 2, 100851. https://doi.org/10.1016/j.xpro.2021.100851.

Björkman, C., Näslund, K., Stenlund, S., Maley, S.W., Buxton, D., and Uggla, A. (1999). An IgG
Avidity ELISA to Discriminate between Recent and Chronic Neospora Caninum Infection. J. Vet.
Diagn. Invest. *11*, 41–44. https://doi.org/10.1177/104063879901100106.

Caillard, S., Chavarot, N., Bertrand, D., Kamar, N., Thaunat, O., Moal, V., Masset, C., Hazzan,
M., Gatault, P., Sicard, A., et al. (2021). Occurrence of severe COVID-19 in vaccinated transplant
patients. Kidney Int. *100*, 477–479. https://doi.org/10.1016/j.kint.2021.05.011.

Chan, C.M., Tse, H., Wong, S.S.Y., Woo, P.C.Y., Lau, S.K.P., Chen, L., Zheng, B.J., Huang, J.D.,
and Yuen, K.Y. (2009). Examination of seroprevalence of coronavirus HKU1 infection with S
protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J. Clin. Virol.
45, 54–60. https://doi.org/10.1016/j.jcv.2009.02.011.

540 Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., Beaudoin-541 Bussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022). SARS-CoV-2 Omicron Spike 542 recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week 543 interval between doses. Cell Rep. 110429. https://doi.org/10.1016/j.celrep.2022.110429.

- 544 CST (2022). National Transplant Consensus Guidance on COVID-19 Vaccine, chrome-545 https://www.cst-
- 546 transplant.ca/_Library/Coronavirus/National_Transplant_Consensus_Guidance_on_COVID_Va
- 547 ccine_2022_1_final_1_.pdf.

548 Danziger-Isakov, L., Blumberg, E.A., Manuel, O., and Sester, M. (2021). Impact of COVID-19 in 549 solid organ transplant recipients. Am. J. Transplant. *21*, 925–937. 550 https://doi.org/10.1111/ajt.16449.

551 Fialová, L., Petráčková, M., and Kuchař, O. (2017). Comparison of different enzyme-linked 552 immunosorbent assay methods for avidity determination of antiphospholipid antibodies. J. Clin. 553 Lab. Anal. *31*, e22121. https://doi.org/10.1002/jcla.22121.

Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D.,
Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to selected
SARS-CoV-2 emerging variants spike antigenicity. Virology *563*, 134–145.
https://doi.org/10.1016/j.virol.2021.09.001.

Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K., Seydoux,
E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization of crossneutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. *36*, 109353.
https://doi.org/10.1016/j.celrep.2021.109353.

Kumar, D., Blumberg, E.A., Danziger-Isakov, L., Kotton, C.N., Halasa, N.B., Ison, M.G., Avery,
R.K., Green, M., Allen, U.D., Edwards, K.M., et al. (2011). Influenza Vaccination in the Organ
Transplant Recipient: Review and Summary Recommendations[†]. Am. J. Transplant. *11*, 2020–
2030. https://doi.org/10.1111/j.1600-6143.2011.03753.x.

Kumar, S., Thambiraja, T.S., Karuppanan, K., and Subramaniam, G. (2022). Omicron and Delta
variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. *94*,
1641–1649. https://doi.org/10.1002/jmv.27526.

Lauring, A.S., Tenforde, M.W., Chappell, J.D., Gaglani, M., Ginde, A.A., McNeal, T., Ghamande,
S., Douin, D.J., Talbot, H.K., Casey, J.D., et al. (2022). Clinical severity of, and effectiveness of
mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the
United States: prospective observational study. BMJ 376, e069761. https://doi.org/10.1136/bmj2021-069761.

Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,
Anand, S.P., et al. (2022). Structural basis and mode of action for two broadly neutralizing
antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. *38*, 110210.
https://doi.org/10.1016/j.celrep.2021.110210.

Meulen, J. ter, Brink, E.N. van den, Poon, L.L.M., Marissen, W.E., Leung, C.S.W., Cox, F.,
Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., Deventer, E. van, et al. (2006). Human Monoclonal
Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.
PLOS Med. 3, e237. https://doi.org/10.1371/journal.pmed.0030237.

582 Miele, M., Busà, R., Russelli, G., Sorrentino, M.C., Di Bella, M., Timoneri, F., Mularoni, A., 583 Panarello, G., Vitulo, P., Conaldi, P.G., et al. (2021). Impaired anti-SARS-CoV-2 Humoral and 584 Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid 585 Organ Transplanted Patients. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. 586 Surg. https://doi.org/10.1111/ajt.16702.

Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N.,
Beaudoin-Bussières, G., Vézina, D., et al. (2021). Temporal associations of B and T cell immunity
with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. BioRxiv Prepr.
Serv. Biol. 2021.12.18.473317. https://doi.org/10.1101/2021.12.18.473317.

591 Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S., 592 Regev-Yochay, G., Mendelson, E., et al. (2022). Third BNT162b2 Vaccination Neutralization of 593 SARS-CoV-2 Omicron Infection. N. Engl. Med. 386, 492-494. J. 594 https://doi.org/10.1056/NEJMc2119358.

595 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N., 596 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended 597 dosina intervals BNT162b2 mRNA vaccine. Cell 5699-5714.e11. of 184. 598 https://doi.org/10.1016/j.cell.2021.10.011.

Pereira, M.R., Mohan, S., Cohen, D.J., Husain, S.A., Dube, G.K., Ratner, L.E., Arcasoy, S.,
Aversa, M.M., Benvenuto, L.J., Dadhania, D.M., et al. (2020). COVID-19 in solid organ transplant
recipients: Initial report from the US epicenter. Am. J. Transplant. 20, 1800–1808.
https://doi.org/10.1111/ajt.15941.

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland,
W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021). Considerable escape of SARS-CoV-2
Omicron to antibody neutralization. Nature 1–7. https://doi.org/10.1038/s41586-021-04389-z.

Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA
Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615. https://doi.org/10.1056/NEJMoa2034577.

609 Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, 610 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral 611 Responses against SARS-CoV-2 Spike. Med. 100126. Cell Rep. 1, 612 https://doi.org/10.1016/j.xcrm.2020.100126.

R Core Team (2014). R: A language and environment for statistical computing. R Foundation for
 Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.

Rabinowich, L., Grupper, A., Baruch, R., Ben-Yehoyada, M., Halperin, T., Turner, D., Katchman,
E., Levi, S., Houri, I., Lubezky, N., et al. (2021). Low immunogenicity to SARS-CoV-2 vaccination
among liver transplant recipients. J. Hepatol. 75, 435–438.
https://doi.org/10.1016/j.jhep.2021.04.020.

Rees, E.M., Waterlow, N.R., Lowe, R., and Kucharski, A.J. (2021). Estimating the duration of
seropositivity of human seasonal coronaviruses using seroprevalence studies. Wellcome Open
Res. *6*, 138. https://doi.org/10.12688/wellcomeopenres.16701.3.

Richardson, S.I., Manamela, N.P., Motsoeneng, B.M., Kaldine, H., Ayres, F., Makhado, Z.,
Mennen, M., Skelem, S., Williams, N., Sullivan, N.J., et al. (2022). SARS-CoV-2 Beta and Delta

variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. *3*, 100510.
 https://doi.org/10.1016/j.xcrm.2022.100510.

Rincon-Arevalo, H., Choi, M., Stefanski, A.-L., Halleck, F., Weber, U., Szelinski, F., Jahrsdörfer,
B., Schrezenmeier, H., Ludwig, C., Sattler, A., et al. (2021). Impaired humoral immunity to SARSCoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. *6*,
eabj1031. https://doi.org/10.1126/sciimmunol.abj1031.

Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler,
C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the SARS-CoV-2
Omicron Variant. N. Engl. J. Med. *386*, 599–601. https://doi.org/10.1056/NEJMc2119641.

Sheikhi, K., Shirzadfar, H., and Sheikhi, M. (2020). A Review on Novel Coronavirus (Covid-19):
Symptoms, Transmission and Diagnosis Tests. Res. Infect. Dis. Trop. Med. 2, 1–8.
https://doi.org/10.33702/ridtm.2020.2.1.1.

Stucchi, R.S.B., Lopes, M.H., Kumar, D., and Manuel, O. (2018). Vaccine Recommendations for
Solid-Organ Transplant Recipients and Donors. Transplantation *102*, S72.
https://doi.org/10.1097/TP.00000000002012.

- Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schwöbel, J., Anders, L., Faulhaber-Walter, R.,
 Schewe, J., Martin, H., Schirutschke, H., et al. (2021). Humoral and cellular immunity to SARSCoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter
 observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg. Health Eur.
 9, 100178. https://doi.org/10.1016/j.lanepe.2021.100178.
- Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussières, G., Brassard,
 N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine
 BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe *0.* https://doi.org/10.1016/j.chom.2021.06.001.

Tauzin, A., Gong, S.Y., Painter, M.M., Goel, R.R., Chatterjee, D., Beaudoin-Bussières, G.,
Marchitto, L., Boutin, M., Laumaea, A., Okeny, J., et al. (2022a). A boost with SARS-CoV-2
BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between
the first two doses. 2022.04.18.22273967. https://doi.org/10.1101/2022.04.18.22273967.

Tauzin, A., Gendron-Lepage, G., Nayrac, M., Anand, S.P., Bourassa, C., Medjahed, H., Goyette,
G., Dubé, M., Bazin, R., Kaufmann, D.E., et al. (2022b). Evolution of Anti-RBD IgG Avidity
Following SARS-CoV-2 Infection. Viruses *14*, 532. https://doi.org/10.3390/v14030532.

Tauzin, A., Gong, S.Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L.,
Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022c). Strong humoral immune responses
against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between
doses. Cell Host Microbe *30*, 97-109.e5. https://doi.org/10.1016/j.chom.2021.12.004.

Tseng, H.F., Ackerson, B.K., Luo, Y., Sy, L.S., Talarico, C.A., Tian, Y., Bruxvoort, K.J., Tubert,
J.E., Florea, A., Ku, J.H., et al. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2
Omicron and Delta variants. Nat. Med. 1–9. https://doi.org/10.1038/s41591-022-01753-y.

Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussières, G.,
Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice

reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity S1074-7613(21)00347-2. https://doi.org/10.1016/j.immuni.2021.08.015.

Yoon, S.K., Hegmann, K.T., Thiese, M.S., Burgess, J.L., Ellingson, K., Lutrick, K., Olsho, L.E.W.,
Edwards, L.J., Sokol, B., Caban-Martinez, A.J., et al. (2022). Protection with a Third Dose of
mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N. Engl. J. Med. *0*, null.
https://doi.org/10.1056/NEJMc2201821.









Mean : 22.4 10.4 17.2 5.82 18.5

ADCC

ADCC Mean: 24.0 20.2 16.2 17.2 23.3

ADCC Mean ; 22.4 24.0 10.4 20.2 17.2 16.2 5.82 17.2 18.5 23.3 В

D

D614G 80

Mean : 1020

D614G 249 656 162 163

D614G Mean: 869 1020 80 249 632 656 41 162 184 163









Delta













Omicron



**

.000

HCW Kidney Liver Lung Heart

After the third dose

G 10000-

1000

10-

Ę,

129 Mean : 1041 890 46 170 236 111 48 61 42 129



Omicron





After the third dose





Figure S1 : Recognition of SARS-CoV-2 Spike variants by vaccinated solid organ transplant recipients, Related to Figure 2.

293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants and stained with the CV3-25 Ab or with plasma from HCW (**A**) or transplant recipients (**B-E**) collected after the second and third doses of mRNA vaccine. The values represent the MFI normalized by the CV3-25 Ab. Symbols represent biologically independent samples from transplant recipients and HCW. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* p < 0.05; ** p < 0.01; **** p < 0.001; **** p <



Figure S2 : Neutralization of SARS-CoV-2 Spike variants by vaccinated solid organ transplant recipients, Related to Figure 3.

Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins with serial dilutions of plasma from HCW (**A**) and transplant recipients (**B-E**) collected after the second and third doses of mRNA vaccine for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID₅₀) values were determined using a normalized non-linear regression using GraphPad Prism software. Symbols represent biologically independent samples from transplant recipients and HCW. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* p < 0.05; ** p < 0.001; **** p < 0.0001; ns, non-significant).